HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that its management team will participate in several investor and industry conferences throughout March 2026. The company's executives will use these platforms to showcase its FDA-cleared technology and engage with investors, physicians, and potential partners.
CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17. Eno will deliver a webcast presentation on March 16, and both executives will meet with institutional and retail investors during the event. The company will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion on technologies advancing healthy aging.
Most significantly, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30. At this premier cardiology event, HeartBeam will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. The company's latest news and updates are available in its newsroom at https://ibn.fm/BEAT.
This conference participation is important because it represents HeartBeam's strategic effort to gain broader recognition for its innovative cardiac monitoring technology. The company has developed what it describes as the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, potentially enabling physicians to identify cardiac health trends and acute conditions outside of traditional medical facilities.
The technology's regulatory status adds significance to these presentations. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology. Details on the intended use of its technology are available in the company's Cleared Indications for Use at https://www.heartbeam.com/indications.
For the healthcare industry, HeartBeam's technology represents a potential shift toward more accessible cardiac monitoring. If successfully adopted, it could enable earlier detection of cardiac issues and more continuous monitoring of patients with heart conditions, potentially reducing hospital visits and improving outcomes. For investors, the conference presentations provide opportunities to assess the company's growth prospects and technology adoption in a competitive medical device market. The company's participation in these high-profile events suggests confidence in both its technology and its commercial strategy as it seeks to establish itself in the cardiac care market.
